Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon, Veritas Partner to Apply AI to Next Generation of Variant Classification

NEW YORK (GenomeWeb) – DNA sequencing company Veritas Genetics is partnering with genomic literature search engine Genomenon in an effort to move literature prioritization forward with the help of artificial intelligence.

The two companies said today that they would apply genomic language processing, machine learning, and AI to develop a new literature prioritization engine, following established variant classification schemes. Toward this goal, Veritas will integrate Genomenon's Mastermind analytic and data visualization tool into its own genome interpretation technology and advise Genomenon on enhancements to Mastermind.

In announcing the partnership, Ann Arbor, Michigan-based Genomenon called WGS interpretation the "single most critical hurdle to realize the promise of genomic medicine." Through this deal, the companies hope to drive down the cost and improve accuracy of variant classification while simplifying updates to classifications as the science advances.  

"Variant classification sits at the center of the genomic revolution," Genomenon CEO Mike Klein said in a statement. "We look forward to radically moving the field forward through our collective expertise and variant interpretation tools."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.